Digital

India’s GLP-1 market value rose 72% year-on-year in September 2026, despite a 10% drop in units sold, as newer products—largely generic semaglutide—drove growth. The broader anti-obesity market reached Rs 287.9 crore. Tirzepatide led with 57.5% of sales; Mounjaro remained the top-selling drug.